Oxford Biomedica plc
OXB.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £335,564 | £445,037 | £312,427 | £212,497 |
| - Cash | £53,877 | £60,650 | £81,409 | £103,716 |
| + Debt | £105,424 | £108,761 | £110,307 | £111,458 |
| Enterprise Value | £387,111 | £493,148 | £341,325 | £220,239 |
| Revenue | £73,223 | £77,991 | £50,806 | £46,478 |
| % Growth | -6.1% | 53.5% | 9.3% | – |
| Gross Profit | £31,657 | £34,719 | £17,955 | £17,788 |
| % Margin | 43.2% | 44.5% | 35.3% | 38.3% |
| EBITDA | -£6,095 | £5,020 | -£19,674 | -£112,225 |
| % Margin | -8.3% | 6.4% | -38.7% | -241.5% |
| Net Income | -£26,360 | -£10,705 | -£32,485 | -£109,534 |
| % Margin | -36% | -13.7% | -63.9% | -235.7% |
| EPS Diluted | -0.25 | -0.1 | -0.31 | -1.13 |
| % Growth | -150% | 67.7% | 72.6% | – |
| Operating Cash Flow | £2,354 | -£11,851 | -£39,199 | -£23,103 |
| Capital Expenditures | -£1,509 | -£2,683 | -£4,813 | -£4,978 |
| Free Cash Flow | £845 | -£14,534 | -£44,012 | -£28,081 |